Royalty Pharma Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Royalty Pharma Plc on April 4, 2022, covering the event date of April 1, 2022. The filing addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance regarding the audit firm.
Material Changes
On April 1, 2022, the Audit Committee of the Board of Directors executed the following changes:
- Appointed Ernst & Young LLP (EY US) as the independent registered public accounting firm for U.S. reporting purposes, effective immediately.
- Accepted the resignation of Ernst & Young Chartered Accountants (EY Ireland) as the independent registered public accounting firm for U.S. reporting purposes, effective immediately.
- Retained EY Ireland as the statutory auditor for filings with Companies House in the United Kingdom.
The Company stated the change was made to facilitate the logistics of financial reporting in the United States.
Guidance, Outlook, and Risks
The filing confirms that the reports of EY Ireland for the fiscal years ended December 31, 2021, and 2020, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles. Furthermore, there were no disagreements with EY Ireland on accounting principles or practices, nor were there any reportable events during the relevant periods. No new guidance or outlook was provided in this filing.
Investor Verification Checklist
- Verify the effective date of the transition from EY Ireland to EY US for U.S. filings (April 1, 2022).
- Confirm that EY Ireland remains the statutory auditor for UK regulatory filings.
- Review the letter from EY Ireland (Exhibit 16.1) to ensure no undisclosed disagreements or reportable events exist.
- Monitor future filings to confirm EY US's engagement for the fiscal year ending December 31, 2022.